{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"FANCA is a tumor suppressor and DNA repair protein. Germline mutations of FANCA are associated with the cancer predisposition syndrome Fanconi Anemia.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"11/16/2020",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "12637330",
        "11739169",
        "21273304",
        "12827451"
      ]
    },
    "description":"FANCA truncating mutations can produce several forms of C-terminally truncated proteins and have been shown to result in the complete loss of FANCA protein expression (PMID: 21273304). These mutations have been found in Fanconi anemia (PMID: 12827451). In vitro studies demonstrated that loss of FANCA results in sensitization of Fanconi anemia fibroblast cells to DNA cross-linking agents such as mitomycin C when as measured by decreased cell proliferation upon drug treatment (PMID: 11739169, 12637330).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"W911Dfs*31",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":2175,
    "hgvs":null,
    "hugoSymbol":"FANCA",
    "id":null,
    "proteinEnd":911,
    "proteinStart":910,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The FANCA W911Dfs*31 mutation is likely oncogenic.",
  "vus":false
}